» Articles » PMID: 38004434

Pharmacokinetics in Pharmacometabolomics: Towards Personalized Medication

Overview
Publisher MDPI
Specialty Chemistry
Date 2023 Nov 25
PMID 38004434
Authors
Affiliations
Soon will be listed here.
Abstract

Indiscriminate drug administration may lead to drug therapy results with varying effects on patients, and the proposal of personalized medication can help patients to receive effective drug therapy. Conventional ways of personalized medication, such as pharmacogenomics and therapeutic drug monitoring (TDM), can only be implemented from a single perspective. The development of pharmacometabolomics provides a research method for the realization of precise drug administration, which integrates the environmental and genetic factors, and applies metabolomics technology to study how to predict different drug therapeutic responses of organisms based on baseline metabolic levels. The published research on pharmacometabolomics has achieved satisfactory results in predicting the pharmacokinetics, pharmacodynamics, and the discovery of biomarkers of drugs. Among them, the pharmacokinetics related to pharmacometabolomics are used to explore individual variability in drug metabolism from the level of metabolism of the drugs in vivo and the level of endogenous metabolite changes. By searching for relevant literature with the keyword "pharmacometabolomics" on the two major literature retrieval websites, PubMed and Web of Science, from 2006 to 2023, we reviewed articles in the field of pharmacometabolomics that incorporated pharmacokinetics into their research. This review explains the therapeutic effects of drugs on the body from the perspective of endogenous metabolites and pharmacokinetic principles, and reports the latest advances in pharmacometabolomics related to pharmacokinetics to provide research ideas and methods for advancing the implementation of personalized medication.

Citing Articles

Pharmacometabolomics Enables Real-World Drug Metabolism Sciences.

Nijdam F, Hof M, Blokzijl H, Bakker S, Hak E, Hopfgartner G Metabolites. 2025; 15(1).

PMID: 39852382 PMC: 11767479. DOI: 10.3390/metabo15010039.


Global research trends in therapeutic drug monitoring of antimicrobials from 2000 to 2023: a bibliometric analysis.

Li H, Jiang M, Kong L Front Pharmacol. 2024; 15:1474878.

PMID: 39691397 PMC: 11649425. DOI: 10.3389/fphar.2024.1474878.


CPMKG: a condition-based knowledge graph for precision medicine.

Yang J, Zhuang X, Li Z, Xiong G, Xu P, Ling Y Database (Oxford). 2024; 2024.

PMID: 39331730 PMC: 11429523. DOI: 10.1093/database/baae102.


Allicin: a promising modulator of apoptosis and survival signaling in cancer.

Bhuker S, Kaur A, Rajauria K, Tuli H, Saini A, Saini R Med Oncol. 2024; 41(9):210.

PMID: 39060753 DOI: 10.1007/s12032-024-02459-6.


Therapeutic Drug Monitoring and Biomarkers; towards Better Dosing of Antimicrobial Therapy.

Wehbe E, Patanwala A, Lu C, Kim H, Stocker S, Alffenaar J Pharmaceutics. 2024; 16(5).

PMID: 38794338 PMC: 11125587. DOI: 10.3390/pharmaceutics16050677.


References
1.
Ji Y, Hebbring S, Zhu H, Jenkins G, Biernacka J, Snyder K . Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. Clin Pharmacol Ther. 2010; 89(1):97-104. PMC: 3034442. DOI: 10.1038/clpt.2010.250. View

2.
Cristoni S, Bernardi L, Malvandi A, Larini M, Longhi E, Sortino F . A case of personalized and precision medicine: Pharmacometabolomic applications to rare cancer, microbiological investigation, and therapy. Rapid Commun Mass Spectrom. 2020; 35(2):e8976. DOI: 10.1002/rcm.8976. View

3.
Shaaban A, Zainal H, Khalil N, Abd Aziz F, Chng E, Teh C . Prediction of Low-Dose Aspirin-Induced Gastric Toxicity Using Nuclear Magnetic Resonance Spectroscopy-Based Pharmacometabolomics in Rats. Molecules. 2022; 27(7). PMC: 9000689. DOI: 10.3390/molecules27072126. View

4.
Reis Silveira A, Duarte G, de Piloto Fernandes A, Garcia P, Vieira N, Antonio M . Serum Predose Metabolic Profiling for Prediction of Rosuvastatin Pharmacokinetic Parameters in Healthy Volunteers. Front Pharmacol. 2021; 12:752960. PMC: 8633954. DOI: 10.3389/fphar.2021.752960. View

5.
Tee K, Ibrahim L, Hashim N, Saiman M, Zakaria Z, Huri H . Pharmacokinetic-Pharmacometabolomic Approach in Early-Phase Clinical Trials: A Way Forward for Targeted Therapy in Type 2 Diabetes. Pharmaceutics. 2022; 14(6). PMC: 9231303. DOI: 10.3390/pharmaceutics14061268. View